US Government As Represented by the Secretary of the Army

National Institutes of Health, a Component of the US Dept. of Health & Human Services

USA As Represented by Secretary of the Navy

The Walter Reed Army Institute of Research

Joseph R Putnak

Kenneth H Eckels

Stephen Whitehead

Brian R Murphy

Robert M Chanock

Alexander G Pletnev

Bruce L Innis

Joseph E Blaney

Doria R Dubois

Charles H Hoke

David Vaughn

Monika Simmons

Joseph E Blaney, Jr

Stephen J Thomas

Sun Wellington

Niranjan Kanessa-thasan

Niranian Kanesa-thasan

Erik A Henchai

Stephen S Whitehead

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,

Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus

The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.

The invention relates to a method for preventing, ameliorating or treating disease caused by dengue virus in a subject in need thereof comprising administering to the subject a dengue vaccine formulation in combination with a NS3 helicase polypeptide and/or fragment(s) thereof, wherein said method comprises stimulating humoral as well as cell-mediated immunity to the dengue virus in the subject.

Immune enhancing recombinant dengue protein

Immunogenic compositions comprising one or more inactivated dengue viruses and one or more inactivated non-dengue flaviviruses and methods of making and using thereof are provided.

Combination purified inactivated vaccine for flaviviruses

The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.

Multivalent dengue virus vaccine

The present invention provides a method for replicating virus to high titer in cultured mammalian cells by infecting the mammalian cells with the high titer virus strain to obtain infected cells, specifically, attenuated dengue virus strains of serotype 1, 2, 3, and 4. The resulting replicated virus is suitable for use in vaccines and vaccination methods which are also provided by the invention.

Adaptation of virus to vertebrate cells

The present invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.

Attenuated dengue-4 virus vaccine

The present invention provides immunogenic compositions of attenuated dengue-1 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-1 virus by administration of attenuated dengue-1 virus.

Attenuated dengue-3 virus vaccine

The present invention provides vaccine compositions of attenuated dengue-2 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-2 virus by administration of attenuated dengue-2 virus.

Growing community of inventors

Silver Spring, MD, United States of America

Joseph R Putnak